1. Home
  2. VYGR

VYGR

Voyager Therapeutics Inc.

Logo Voyager Therapeutics Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-22-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.

Founded: 2013 Country:
United States
United States
Employees: N/A City: LEXINGTON
Market Cap: 410.0M IPO Year: 2015
Target Price: $18.57 AVG Volume (30 days): 640.4K
Analyst Decision: Strong Buy Number of Analysts: 7
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: 2.97 EPS Growth: N/A
52 Week Low/High: $6.06 - $14.34 Next Earning Date: 05-07-2024
Revenue: $250,008,000 Revenue Growth: 511.16%
Revenue Growth (this year): -84.15% Revenue Growth (next year): 39.28%

Share on Social Networks: